Experts discuss survival data from the TiNivo-2 phase 3 trial and practical approaches to dose management in clinical practice.

Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

Experts discuss patient-reported outcomes from the TiNivo-2 trial, focusing on quality of life and the treatment experience.

Documentation is especially important for nurse practitioners in cancer research and can lead to improved patient recruitment ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Experts discuss sequencing strategies in renal cell carcinoma (RCC), focusing on optimizing treatment selection after ...

The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in ...

The WOLVERINE meta-analysis reinforces the role of MDT in delaying disease progression in patients with oligometastatic ...

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by ...

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy. Lerociclib plus fulvestrant demonstrated a ...

Seth Eisenberg, ASN, RN, OCN, BMTCN, explained his research on a toilet cover for oncology nurses to potentially reduce ...